Biotechnology Company Founded on Weill Cornell Technology Announced $90 Million Series A Financing to Advance Radioantibody Treatment for Cancer
May 8, 2023
Convergent Therapeutics Inc., a clinical-stage biotechnology company co-founded by Dr. Neil Bander, the Bernard and Josephine Chaus Professor of Urologic Oncology, announced May 3 the completion of a $90 million Series A financing. Convergent focuses on developing next-generation radiopharmaceuticals for the treatment of cancer. The financing will support its development of a pipeline of novel radioantibodies, including its lead program with CONV01-α, for the treatment of advanced prostate cancer.
Robert Langer ’70 Receives Engineering’s Highest Alumni Honor
April 21, 2023
He is the most cited engineer in history. He holds more than 1,400 patents. His pioneering work in biotechnology, drug delivery and tissue engineering has made him one of the most prolific inventors in medicine, and he has co-founded more than 40 companies, including Moderna. For this and many other achievements, Robert Langer ’70 received the Cornell Engineering Distinguished Alumni Award during a celebration hosted Apr. 19 in the Duffield Hall Atrium at Cornell University.
Bioentrepreneurship Initiative Fosters Entrepreneurial Community
April 12, 2023
Members of the Cornell entrepreneurial community gathered to celebrate a successful first year of the BioEntrepreneurship Initiative at the program’s culminating workshop on March 18 at Cornell’s academic space in Midtown Manhattan. In its inaugural year, the program of the Cornell SC Johnson College of Business unified MBA students and researchers to develop the next generation of life-science startup C-suite leaders and encouraged collaboration between Cornell’s Ithaca and New York campuses.
Student Teams Tackle Pressing Health Concerns During Health Hackathon
March 30, 2023
Asthma is personal for Tyler Bershad. “Like 26 million Americans, I have asthma,” said Bershad, an MBA candidate in business administration at Cornell Tech, during the 2023 Health Hackathon in February. “Asthma is the most prevalent chronic respiratory disease in humans and, unfortunately, those who are most vulnerable are children.”
3D-Printed Scaffold Could Improve Breast Reconstruction Results
March 8, 2023
Weill Cornell Medicine investigators have developed a technique to help surgeons reconstruct more natural-looking nipples for patients who have undergone breast reconstruction after mastectomy to treat breast cancer.
Startup Symposium & InvestConnect Conference Showcases Weill Cornell Medicine Newcos and Spinouts
March 6, 2023
Dr. Behzad Aghazadeh’s professional ambition carried him to different continents, scientific disciplines and career focuses. But the one constant for the Weill Cornell Medicine alumnus has been a commitment to entrepreneurship.
Radiation Oncologist Partners with Enterprise Innovation to Improve Women's Health Technology
February 17, 2023
In recognition of Cervical Health Awareness Month, Enterprise Innovation spoke with radiation oncologist Dr. Onyinye Balogun about her efforts to improve women's health technology. Dr. Balogun shared how an encounter with a cervical cancer patient inspired her to become an entrepreneur.
Neuroscientist Highlights Role of Enterprise Innovation in Advancing Translational Research
February 17, 2023
Enterprise Innovation interviewed rising innovator Dr. Anna Orr. In this conversation, Dr. Orr shares the translational research in neuroscience that is being conducted in her lab as well as how early-career faculty can leverage resources offered by the Weill Cornell Medicine innovation ecosystem to advance their discoveries.
On-Demand Male Contraceptive Shows Promise in Preclinical Study
February 14, 2023
An experimental contraceptive drug candidate developed by Weill Cornell Medicine investigators temporarily stops sperm in their tracks and prevents pregnancies in preclinical models. The study, published in Nature Communications on Feb. 14, demonstrates that an on-demand male contraceptive is possible.
Accelerating BioVenture Innovation Advances Another Cohort of Aspiring Entrepreneurs
December 16, 2022
BioVenture eLab’s intense 15-week Accelerating BioVenture Innovation (ABI) course culminated in an energizing pitch competition on Dec. 6 at Griffis Faculty Club.